Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nichi-Iko Takes Share Of Korean Biosimilar Firm Aprogen, Gains Japanese Rights For Remicade And Herceptin Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

Aprogen - founded in 2000 and an affiliate of Korean firm Schnell Biopharmaceuticals - is currently in talks with pharmas in Europe and Central and South America for biosimilar licensing deals.

You may also be interested in...

Korea's Celltrion Completes Phase I Clinical Trials For Biosimilars Based On Roche And Johnson & Johnson Products

SEOUL - South Korean biotech firm Celltrion said it has successfully completed Phase I clinical trials on its biosimilar versions of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade(infliximab)

Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan

Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan

Roche, Novartis, Lilly, J&J: Earnings Call Roundup For Emerging Markets

In a recurring feature, PharmAsia News monitors major earnings calls to report on new trends in emerging market strategies.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts